Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Tyrosine kinase inhibitors (TKIs) are first line treatment for non-small-cell lung cancer patients with mutations in targeted genes. TKIs are metabolized in liver into inactive metabolites before eliminating from body. Liver function might plays a significant role in inter-individual differences of pharmacokinetics of TKIs. Hepatitis B is a disease of high prevalence in south China. The liver function will be compromised if the infection of hepatitis B virus has not been controlled. This study aims to compare the pharmacokinetics of TKIs before and after controlling HBV with standard treatment in Chinese patients of non-small-cell lung cancer.
Age
18–70
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
pathological confirmed non-small-cell lung cancer
with epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genetic mutation required by different TKIs
liver function, ALT and/or AST \<= 2\*upper limit of normal (ULN)
diagnosed of chronic hepatitis B
Hepatitis B negative as controlled group
receiving one type of TKIs
Age between 18-70
You may not be if
diagnosed of acute/ active hepatitis B
diagnosed of AIDS
unable to make decision because of metastasis to central nervous system
